They found that MAG-Tn3 induced Tn-specific antibodies that killed Tn-positive cancer cells of human and MAG-Tn3 was now being evaluated for cancer vaccine in breast cancer patients (phase I clinical trial). The gene discussed is MAG; the disease is breast carcinoma.